Atrion (NASDAQ:ATRI) Lifted to “Strong-Buy” at BidaskClub

Atrion (NASDAQ:ATRI) was upgraded by stock analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Wednesday, March 27th, BidAskClub reports.

Separately, ValuEngine upgraded shares of Atrion from a “hold” rating to a “buy” rating in a report on Monday, February 4th.

Shares of NASDAQ ATRI traded up $6.47 during midday trading on Wednesday, hitting $869.97. The company had a trading volume of 4,201 shares, compared to its average volume of 6,550. Atrion has a twelve month low of $560.65 and a twelve month high of $948.03. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of 47.31 and a beta of 0.44.

Large investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. purchased a new position in Atrion during the 4th quarter valued at about $130,000. Amundi Pioneer Asset Management Inc. purchased a new stake in shares of Atrion during the fourth quarter worth about $148,000. Quantamental Technologies LLC purchased a new stake in shares of Atrion during the fourth quarter worth about $149,000. Paradigm Financial Advisors LLC purchased a new stake in shares of Atrion during the first quarter worth about $211,000. Finally, Legal & General Group Plc grew its holdings in shares of Atrion by 7.8% during the fourth quarter. Legal & General Group Plc now owns 249 shares of the medical instruments supplier’s stock worth $185,000 after buying an additional 18 shares in the last quarter. Hedge funds and other institutional investors own 61.74% of the company’s stock.

About Atrion

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Featured Article: What is an investor looking for in an SEC filing?

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.